Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 28, 2026
Is AstraZeneca (LSE:AZN) Offering Value After Recent Share Price Pullback
View original at finance.yahoo.comIs AstraZeneca (LSE:AZN) Offering Value After Recent Share Price Pullback Never miss an important update on your stock portfolio and cut through the noise…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
The DCF model points to an estimated intrinsic value of £242.86 per share compared with the current share price of £143.02, implying shares trade at a 41.1% discount to fair value
60% confidenceAstraZeneca is undervalued by 41.1% according to Discounted Cash Flow analysis
60% confidenceAstraZeneca currently scores 3 out of 6 on Simply Wall St's valuation checks, meaning the company screens as undervalued on half of the tests used
60% confidence
Data points we hold from this source
| AstraZeneca AB · free cash flow projected | 20.2 USD |
| AstraZeneca AB · intrinsic value per share | 242.86 GBP |
| AstraZeneca AB · stock return 1 month | -6.0 percent |
| AstraZeneca AB · stock return 1 week | 2.9 percent |
| AstraZeneca AB · stock return 1 year | 27.5 percent |
| AstraZeneca AB · stock return 3 year | 35.2 percent |
| AstraZeneca AB · stock return 5 year | 121.6 percent |